Laying the foundation for greater value in inflammatory bowel disease care
There may be potential to accelerate uptake of value-based healthcare for subspecialty conditions that experience high variability in cost and outcomes, sometimes described as “high-beta” conditions.[i] Inflammatory bowel disease (IBD), an umbrella term for two autoimmune diseases—ulcerative colitis and Crohn’s disease—impacts an estimated 3.1 million (or 1.3%) of Americans and is a high-beta condition that some stakeholders believe would benefit from value-based approaches, especially at a time of change in the treatment paradigm for IBD.[ii]
In 2021-2022, Tapestry will collaborate with provider representatives, payers, industry leaders, patient advocacy organizations, and others on an effort to explore how consensus-based value frameworks and enhanced learning platforms can accelerate value-based care and new alternative payment models in this sub-specialty.
In May 2021, Tapestry Networks convened the IBD Progress Summit, an initial multistakeholder meeting to take stock of key challenges in IBD care that should be addressed to arrive at consensus-based approaches to promote value. Participants emphasized three key challenges in IBD care: limited endpoints that fail to account for functional outcomes for patients over long periods of time, a heterogeneous patient population requiring more sophisticated risk stratification, and high variation in care, which could be improved by increased standardization across the specialty and advancing holistic approaches to treatment. In reflecting on these challenges, participants largely agreed that focusing on earlier, preventative intervention for IBD patients is the path to value moving forward. Tapestry will work with the Summit’s sponsor, Arena Pharmaceuticals, and other leaders in this space to understand how new frameworks and incentives can make this vision a reality.